Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Purpose: To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental Design: We analyzed the results of quantitative PCR in 280 patients with CML in chronic phase who achieved complete cytogenetic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2005-05, Vol.11 (9), p.3425-3432
Hauptverfasser:	Jorge Cortes, Moshe Talpaz, Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Mary B. Rios, Hagop Kantarjian
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Benzamides Child Child, Preschool Chromosome Aberrations - drug effects Chronic myeloid leukemia Follow-Up Studies Fusion Proteins, bcr-abl - genetics Humans Imatinib Imatinib Mesylate In Situ Hybridization, Fluorescence Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemias and lymphomas Middle Aged Molecular responses PCR Piperazines - therapeutic use Prognosis Protein-Tyrosine Kinases - antagonists & inhibitors Proto-Oncogene Proteins c-abl - genetics Pyrimidines - therapeutic use Remission Induction Reverse Transcriptase Polymerase Chain Reaction Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!